BioCentury | Jul 29, 2020
Finance

With €27M at launch, Vico revives Prosensa oligonucleotide programs, aims to edit RNA for Rett

...development of a program founder and Chairman Luc Dochez knows well from his time at Prosensa...
...more assets were available to the enterprise that would become Vico. Following its acquisition of Prosensa Holding N.V....
...led Prosensa’s series A round in 2007. Kurma’s Remi Droller held a board seat at Prosensa...
BioCentury | May 31, 2018
Emerging Company Profile

Oral route for HAE

...team members responsible for developing Firazyr at Jerini AG with veterans of rare disease company Prosensa Holding N.V....
...that was better than icatibant,” said CEO Berndt Modig, who was CFO at Jerini and Prosensa...
BioCentury | Jan 12, 2018
Product R&D

Avidity’s affinity for muscle

...of a naked morpholino oligo reported in a 2009 Journal of Gene Medicine study by Prosensa Holding N.V....
...added. Prosensa was acquired by BioMarin Pharmaceutical Inc. in 2015. The company discontinued development of Prosensa’s...
BioCentury | Sep 28, 2017
Product R&D

Wave’s purity progress

...the drug safety monitoring boards for many of the DMD compounds that were developed by Prosensa...
...to giving a systemic oligonucleotide with a phosphorothioate backbone in a naked format,” he said. Prosensa Holding N.V....
BioCentury | Mar 2, 2017
Finance

Speeding up DMD

...therapies, but Miller said Exonics is the non-profit’s largest investment to date. Other investments include Prosensa Holding N.V....
BioCentury | Jun 1, 2016
Company News

BioMarin ending Kyndrisa development

...Kyndrisa's efficacy (see BioCentury Extra, Jan. 14) . BioMarin obtained Kyndrisa via its acquisition of Prosensa Holding N.V....
BioCentury | May 16, 2016
Finance

Global ambitions

...companies: Adaptimmune Therapeutics plc , CRISPR Therapeutics AG , NightstaRx Ltd. , ObsEva S.A. , Prosensa Holding N.V....
...in the NightstaRx investment, while LSP was the local VC that anchored NEA's investment in Prosensa...
BioCentury | Mar 28, 2016
Finance

Back in the game

...north of 6x. Other Gimv exits included the acquisition of Duchenne muscular dystrophy (DMD) company Prosensa Holding N.V....
BioCentury | Jan 25, 2016
Clinical News

Kyndrisa drisapersen regulatory update

...thought some boys benefited from the treatment (see BioCentury, Dec. 7, 2015). Former shareholders of Prosensa Holding N.V....
...from BioMarin that would be triggered if Kyndrisa is approved by May 15. BioMarin acquired Prosensa...
...2014 for $680 million in cash up front and up to $160 million in milestones. Prosensa...
BioCentury | Jan 15, 2016
Top Story

FDA rejects BioMarin's Kyndrisa

...in some patients (see BioCentury, Dec. 7, 2015) . FDA's rejection makes former shareholders of Prosensa Holding N.V....
...from BioMarin that would be triggered if Kyndrisa is approved by May 15. BioMarin acquired Prosensa...
...2014 for $680 million in cash up front and up to $160 million in milestones. Prosensa...
Items per page:
1 - 10 of 158
BioCentury | Jul 29, 2020
Finance

With €27M at launch, Vico revives Prosensa oligonucleotide programs, aims to edit RNA for Rett

...development of a program founder and Chairman Luc Dochez knows well from his time at Prosensa...
...more assets were available to the enterprise that would become Vico. Following its acquisition of Prosensa Holding N.V....
...led Prosensa’s series A round in 2007. Kurma’s Remi Droller held a board seat at Prosensa...
BioCentury | May 31, 2018
Emerging Company Profile

Oral route for HAE

...team members responsible for developing Firazyr at Jerini AG with veterans of rare disease company Prosensa Holding N.V....
...that was better than icatibant,” said CEO Berndt Modig, who was CFO at Jerini and Prosensa...
BioCentury | Jan 12, 2018
Product R&D

Avidity’s affinity for muscle

...of a naked morpholino oligo reported in a 2009 Journal of Gene Medicine study by Prosensa Holding N.V....
...added. Prosensa was acquired by BioMarin Pharmaceutical Inc. in 2015. The company discontinued development of Prosensa’s...
BioCentury | Sep 28, 2017
Product R&D

Wave’s purity progress

...the drug safety monitoring boards for many of the DMD compounds that were developed by Prosensa...
...to giving a systemic oligonucleotide with a phosphorothioate backbone in a naked format,” he said. Prosensa Holding N.V....
BioCentury | Mar 2, 2017
Finance

Speeding up DMD

...therapies, but Miller said Exonics is the non-profit’s largest investment to date. Other investments include Prosensa Holding N.V....
BioCentury | Jun 1, 2016
Company News

BioMarin ending Kyndrisa development

...Kyndrisa's efficacy (see BioCentury Extra, Jan. 14) . BioMarin obtained Kyndrisa via its acquisition of Prosensa Holding N.V....
BioCentury | May 16, 2016
Finance

Global ambitions

...companies: Adaptimmune Therapeutics plc , CRISPR Therapeutics AG , NightstaRx Ltd. , ObsEva S.A. , Prosensa Holding N.V....
...in the NightstaRx investment, while LSP was the local VC that anchored NEA's investment in Prosensa...
BioCentury | Mar 28, 2016
Finance

Back in the game

...north of 6x. Other Gimv exits included the acquisition of Duchenne muscular dystrophy (DMD) company Prosensa Holding N.V....
BioCentury | Jan 25, 2016
Clinical News

Kyndrisa drisapersen regulatory update

...thought some boys benefited from the treatment (see BioCentury, Dec. 7, 2015). Former shareholders of Prosensa Holding N.V....
...from BioMarin that would be triggered if Kyndrisa is approved by May 15. BioMarin acquired Prosensa...
...2014 for $680 million in cash up front and up to $160 million in milestones. Prosensa...
BioCentury | Jan 15, 2016
Top Story

FDA rejects BioMarin's Kyndrisa

...in some patients (see BioCentury, Dec. 7, 2015) . FDA's rejection makes former shareholders of Prosensa Holding N.V....
...from BioMarin that would be triggered if Kyndrisa is approved by May 15. BioMarin acquired Prosensa...
...2014 for $680 million in cash up front and up to $160 million in milestones. Prosensa...
Items per page:
1 - 10 of 158